Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relapsed AML 2001/01
ISRCTN94206677Phase 3Completed
- Sponsor
- Dutch Childhood Oncology Group
- Start
- Jan 2001
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daunorubicin, fludarabine, cytarabine and filgrastim in acute myeloid leukemia (AML) (2 arms), sponsored by Dutch Childhood Oncology Group. Started Jan 2001; status: completed.
02
Drugs
daunorubicinfludarabinecytarabinefilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ISRCTN94206677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN94206677.